X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs PFIZER - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD PFIZER STRIDES SHASUN LTD/
PFIZER
 
P/E (TTM) x 13.2 31.2 42.1% View Chart
P/BV x 1.5 5.0 30.7% View Chart
Dividend Yield % 0.6 0.7 99.6%  

Financials

 STRIDES SHASUN LTD   PFIZER
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
PFIZER
Mar-16
STRIDES SHASUN LTD/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,2752,724 46.8%   
Low Rs9181,611 57.0%   
Sales per share (Unadj.) Rs389.6440.9 88.4%  
Earnings per share (Unadj.) Rs28.048.7 57.4%  
Cash flow per share (Unadj.) Rs48.975.8 64.5%  
Dividends per share (Unadj.) Rs4.5015.00 30.0%  
Dividend yield (eoy) %0.40.7 59.3%  
Book value per share (Unadj.) Rs303.1462.9 65.5%  
Shares outstanding (eoy) m89.4245.75 195.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.9 57.2%   
Avg P/E ratio x39.244.5 88.1%  
P/CF ratio (eoy) x22.428.6 78.4%  
Price / Book Value ratio x3.64.7 77.3%  
Dividend payout %16.130.8 52.2%   
Avg Mkt Cap Rs m98,03699,163 98.9%   
No. of employees `0005.82.9 200.8%   
Total wages/salary Rs m5,8812,758 213.3%   
Avg. sales/employee Rs Th6,005.96,981.7 86.0%   
Avg. wages/employee Rs Th1,014.0954.5 106.2%   
Avg. net profit/employee Rs Th431.2771.1 55.9%   
INCOME DATA
Net Sales Rs m34,83420,170 172.7%  
Other income Rs m1,686857 196.6%   
Total revenues Rs m36,52021,028 173.7%   
Gross profit Rs m6,4284,310 149.1%  
Depreciation Rs m1,8721,239 151.1%   
Interest Rs m2,2695 43,640.4%   
Profit before tax Rs m3,9733,923 101.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,00699 -1,017.2%   
Tax Rs m4701,794 26.2%   
Profit after tax Rs m2,5012,228 112.3%  
Gross profit margin %18.521.4 86.4%  
Effective tax rate %11.845.7 25.9%   
Net profit margin %7.211.0 65.0%  
BALANCE SHEET DATA
Current assets Rs m38,16516,299 234.2%   
Current liabilities Rs m30,4027,594 400.4%   
Net working cap to sales %22.343.2 51.6%  
Current ratio x1.32.1 58.5%  
Inventory Days Days7765 118.5%  
Debtors Days Days10426 405.7%  
Net fixed assets Rs m37,6398,622 436.6%   
Share capital Rs m894458 195.5%   
"Free" reserves Rs m26,21020,722 126.5%   
Net worth Rs m27,10521,180 128.0%   
Long term debt Rs m16,37725 65,508.4%   
Total assets Rs m81,16829,137 278.6%  
Interest coverage x2.8755.5 0.4%   
Debt to equity ratio x0.60 51,189.3%  
Sales to assets ratio x0.40.7 62.0%   
Return on assets %5.97.7 76.7%  
Return on equity %9.210.5 87.7%  
Return on capital %12.119.0 63.5%  
Exports to sales %00.1 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA12 0.0%   
Imports (cif) Rs mNA3,526 0.0%   
Fx inflow Rs m13,46552 26,069.9%   
Fx outflow Rs m4,076140 2,911.6%   
Net fx Rs m9,389-88 -10,629.9%   
CASH FLOW
From Operations Rs m2,8813,436 83.9%  
From Investments Rs m-7,051-6,991 100.9%  
From Financial Activity Rs m3,382-619 -546.6%  
Net Cashflow Rs m-788-4,174 18.9%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 37.8 7.5 504.0%  
FIIs % 8.6 4.9 175.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 23.7 109.3%  
Shareholders   56,241 85,207 66.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   MERCK LTD  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare STRIDES SHASUN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD - AJANTA PHARMA COMPARISON

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS